UY36748A - Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen - Google Patents
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienenInfo
- Publication number
- UY36748A UY36748A UY0001036748A UY36748A UY36748A UY 36748 A UY36748 A UY 36748A UY 0001036748 A UY0001036748 A UY 0001036748A UY 36748 A UY36748 A UY 36748A UY 36748 A UY36748 A UY 36748A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical compositions
- modulators
- aminopiridine
- heteroarilo
- irak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Se describen los compuestos de la Fórmula I , o sales de aquellos, en donde HET, A y R3, son tales como se definen en la memoria descriptiva y en las reivindicaciones. También se describen métodos para usar tales compuestos como moduladores de IRAK4, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles para tratar, prevenir o ralentizar enfermedades inflamatorias y autoinmunitarias, o para el tratamiento contra el cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1877DE2015 | 2015-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36748A true UY36748A (es) | 2016-12-30 |
Family
ID=56322320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036748A UY36748A (es) | 2015-06-24 | 2016-06-23 | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen |
Country Status (9)
Country | Link |
---|---|
US (1) | US10294229B2 (es) |
EP (1) | EP3313840B1 (es) |
JP (1) | JP6843775B2 (es) |
CN (1) | CN107849039B (es) |
AR (1) | AR105113A1 (es) |
ES (1) | ES2745525T3 (es) |
TW (1) | TW201718571A (es) |
UY (1) | UY36748A (es) |
WO (1) | WO2016210034A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
JOP20180011A1 (ar) * | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
SI3621960T1 (sl) | 2017-05-11 | 2021-11-30 | Bristol-Myers Squibb Company | Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji |
CA3076613A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
TWI812649B (zh) * | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
BR112020012997A2 (pt) | 2017-12-26 | 2020-12-01 | Kymera Therapeutics, Inc. | degradadores de irak e usos dos mesmos |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TW202136268A (zh) | 2018-07-13 | 2021-10-01 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
TWI797366B (zh) | 2018-08-13 | 2023-04-01 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
CA3105558C (en) * | 2018-08-13 | 2023-09-26 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
CN109836376B (zh) * | 2019-04-10 | 2022-03-22 | 江苏汉阔生物有限公司 | 一种以2,3-吡啶二羧酸为原料制备2-氯代烟酸的方法 |
US20220267348A1 (en) * | 2019-07-23 | 2022-08-25 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors |
WO2021067967A1 (en) * | 2019-10-04 | 2021-04-08 | University Of Kentucky Research Foundation | Preparation of pyrazolo[3,4-b]pyridines as antimalarials |
MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
CN115335381A (zh) * | 2020-02-19 | 2022-11-11 | 新锐思生物制药股份有限公司 | 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途 |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
WO2022147465A1 (en) * | 2020-12-30 | 2022-07-07 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
US11976071B2 (en) | 2021-08-18 | 2024-05-07 | Gilead Sciences, Inc. | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4541695B2 (ja) | 2001-06-15 | 2010-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしての5−(2−アミノピリミジン−4−イル)ベンズイソキサゾール |
AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
CA2490888C (en) | 2002-06-28 | 2011-05-24 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxamide derivative |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
EP1651636A1 (en) | 2003-07-10 | 2006-05-03 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
US8273759B2 (en) | 2007-06-08 | 2012-09-25 | Bayer Cropscience Ag | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
US20110230467A1 (en) | 2008-11-21 | 2011-09-22 | Astellas Pharma Inc. | 4,6-diaminonicotinamide compound |
MX2011005621A (es) | 2008-11-28 | 2011-06-20 | Kowa Co | Derivado de piridin-3-carboxiamida. |
WO2010144647A1 (en) | 2009-06-12 | 2010-12-16 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
JP5770198B2 (ja) | 2009-10-30 | 2015-08-26 | ヤンセン ファーマシューティカ エヌ.ベー. | オピオイド受容体調節因子としてのフェノキシ置換ピリミジン |
US20190192510A1 (en) | 2010-02-01 | 2019-06-27 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
EP2702064A4 (en) | 2011-04-29 | 2014-10-08 | Icahn School Med Mount Sinai | Kinase Inhibitors |
JP6096219B2 (ja) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物 |
US9242975B2 (en) * | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
CN104169275B (zh) * | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
EP2903617B1 (en) * | 2012-10-08 | 2019-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
JP6204484B2 (ja) | 2012-11-08 | 2017-09-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物 |
EP2922840B1 (en) | 2012-11-08 | 2016-12-21 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
MX2015005272A (es) | 2012-11-08 | 2015-07-14 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa). |
TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
-
2016
- 2016-06-23 JP JP2017566643A patent/JP6843775B2/ja active Active
- 2016-06-23 WO PCT/US2016/038858 patent/WO2016210034A1/en active Application Filing
- 2016-06-23 ES ES16734538T patent/ES2745525T3/es active Active
- 2016-06-23 TW TW105119777A patent/TW201718571A/zh unknown
- 2016-06-23 AR ARP160101892A patent/AR105113A1/es unknown
- 2016-06-23 UY UY0001036748A patent/UY36748A/es not_active Application Discontinuation
- 2016-06-23 US US15/738,362 patent/US10294229B2/en active Active
- 2016-06-23 CN CN201680040987.7A patent/CN107849039B/zh active Active
- 2016-06-23 EP EP16734538.8A patent/EP3313840B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
AR105113A1 (es) | 2017-09-06 |
JP2018522859A (ja) | 2018-08-16 |
CN107849039B (zh) | 2020-07-03 |
EP3313840A1 (en) | 2018-05-02 |
WO2016210034A1 (en) | 2016-12-29 |
US20180186799A1 (en) | 2018-07-05 |
US10294229B2 (en) | 2019-05-21 |
JP6843775B2 (ja) | 2021-03-17 |
ES2745525T3 (es) | 2020-03-02 |
CN107849039A (zh) | 2018-03-27 |
EP3313840B1 (en) | 2019-07-24 |
TW201718571A (zh) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36748A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
UY36747A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen | |
UY36749A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
SV2017005561A (es) | Metodos para tratar infecciones por el virus filoviridae | |
UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CO2017011484A2 (es) | Inhibidores de bromodominio | |
CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
CU24389B1 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
CO2019005059A2 (es) | Inhibidores de magl | |
CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
CO2019005038A2 (es) | Inhibidores de magl | |
CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
ECSP14030779A (es) | Inhibidores del nampt | |
CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201204 |